

#### June 27, 2019

## Alivira Animal Health Limited: Ratings withdrawn

#### **Summary of rated instruments**

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Short-term, Non-fund Based Limits	85.00	85.00	[ICRA]A2+; withdrawn
Short-term, Fund-based Limits	60.00	60.00	[ICRA]A2+; withdrawn
Term Loan	125.00	125.00	[ICRA]BBB+ (Stable); withdrawn
Long-term – Interchangeable	(35.00)	(35.00)	[ICRA]BBB+ (Stable); withdrawn
Short-term – Interchangeable	(35.00)	(35.00)	[ICRA]A2+; withdrawn
Total	270.00	270.00	

\*Instrument details are provided in Annexure-1

### Rationale

The ratings have been withdrawn at the request of the company and upon receipt of the no dues certificates/ no objection certificates from the bankers, in accordance with ICRA's policy on withdrawal and suspension of credit rating.

#### **Key rating drivers**

Key rating drivers have not been captured since the ratings have been withdrawn.

### **Liquidity position**

Liquidity position has not been captured since the ratings have been withdrawn.

## **Analytical approach**

Analytical Approach	Comments
Applicable Rating Methodologies	ICRA Policy on Withdrawal and Suspension of Credit rating Corporate Credit Rating Methodology
Parent / Group Support	Not applicable
Consolidation / Standalone	Not applicable

#### **About the Company:**

Incorporated in 2013, Alivira Animal Health Limited (AAHL), wholly-owned subsidiary of Sequent Scientific Limited (SSL), is engaged in manufacturing veterinary APIs and formulations.

Incorporated in 1985, SSL (standalone) was engaged in the manufacturing human active pharmaceutical ingredients (APIs), which has been demerged with effect from October 01, 2017. SSL is now involved in manufacturing 'Praziquantel'– a human and animal API and intermediates. SSL's wholly-owned subsidiary - Sequent Research Limited - offers analytical services to pharmaceutical industry. SSL's (consolidated) portfolio consists of about 23 commercial products in animal health API and 450 products across 12 dosage forms. Post demerger of the human API business, it has seven manufacturing facilities across India, Spain, Turkey, Brazil and Germany.



In FY2019, SSL (consolidated) reported a profit after tax (PAT) of Rs. 56.9 crore on an operating income (OI) of Rs. 1,039.3 crore, as against a PAT of Rs. 430.8 crore (including an after-tax profit of Rs. 396.3 crore from discontinued operation) on an OI of Rs. 847.8 crore in FY2018.

In FY2018, AAHL (consolidated) reported a PAT of Rs. 7.8 crore on an OI of Rs. 833.7 crore, as against a net loss of Rs. 3.8 crore on an OI of Rs. 657.9 crore in FY2017.

### Key financial indicators (audited, consolidated)

	AAHL Consolidated		SSL Consolidated	
SSL (Consolidated)	FY2017	FY2018	FY2018*	FY2019*
Operating Income (Rs. crore)	657.9	833.7	847.8	1,039.3
PAT (Rs. crore)	-3.8	7.8	430.8	56.9
OPBDIT/ OI (%)	13.0%	12.9%	9.8%	12.0%
RoCE (%)	5.0%	10.0%	40.7%	9.3%
Total Debt/ TNW (times)	1.7	2.0	0.4	0.4
Total Debt/ OPBDIT (times)	4.4	3.8	3.1	2.5
Interest Coverage (times)	2.5	2.6	2.5	3.8

\* based on the financials published on BSE

### Status of non-cooperation with previous CRA: Not applicable

## Any other information: None



# **Rating history for last three years:**

	Instrum ent	m Current Rating (FY2020)				Chronology of Rating History for the Past 3 Years				
		Туре	Amount Rated	ated Outstand ing (Rs Rs. Crore)	Date & rating	Date & Rating in FY2019	Date & Rating in FY2018			Date & Rating in FY2017
			(Rs. crore)		June 2019	July 2018	March 2018	November 2017	October 2017	March 2017
1	Term Loan	Long- term	125.00	90.10*	[ICRA]BBB + (Stable); withdrawn	[ICRA]B BB+ (Stable)	[ICRA]B BB+ (Stable)	Provisional [ICRA]BBB+ (SO)&; withdrawn	Provisional [ICRA]BBB+ (SO)&	Provisional [ICRA]BBB+ (SO)&
3	Fund- based Limits	Short- term	60.00	-	[ICRA]A2+; withdrawn	[ICRA]A 2+	[ICRA]A 2+	[ICRA]A2+ (SO)&	[ICRA]A2+ (SO)&	[ICRA]A2+ (SO)&
4	Non- fund Based Limits	Short- term	85.00	-	[ICRA]BBB + (Stable); withdrawn	[ICRA]B BB+ (Stable)	[ICRA]B BB+ (Stable)	[ICRA]BBB+ (SO) &	[ICRA]BBB+ (SO) &	[ICRA]BBB+ (SO) &
5	Intercha ngeable Limits	Long- term	(35.00)	-	[ICRA]BBB + (Stable); withdrawn	[ICRA]B BB+ (Stable)	[ICRA]B BB+ (Stable)	-	-	-
6	Intercha ngeable Limits	Short- term	(35.00)	-	[ICRA]A2+; withdrawn	[ICRA]A 2+	[ICRA]A 2+	-	-	-

\*As on March 31, 2018; &-> on rating watch with developing implications

# **Complexity level of the rated instrument:**

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website <u>www.icra.in</u>



## **Annexure-1: Instrument Details**

ISIN No	Instrument Name	Date of Issuance	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term Loan	Feb-14	11.70%	Nov-22	125.00	[ICRA]BBB+ (Stable); withdrawn
NA	Standby Letter of Cre	-	-	-	55.00	[ICRA]A2+; withdrawn
NA	Letter of Credit	-	-	-	30.00	[ICRA]A2+; withdrawn
NA	Pre-shipment Export	-	-	-	25.00	[ICRA]A2+; withdrawn
NA	Packing Credit	-	-	-	35.00	[ICRA]A2+; withdrawn
NA	Pre-shipment Export	-	-	-	35.00***	[ICRA]A2+; withdrawn
NA	Working Capital Den	-	-	-	35.00***	[ICRA]A2+; withdrawn
NA	Export Post-shipmer	-	-	-	25.00*	[ICRA]A2+; withdrawn
NA	Purchase Bill Discour	-	-	-	25.00*	[ICRA]A2+; withdrawn
NA	Invoice Financing	-	-	-	25.00*	[ICRA]A2+; withdrawn
NA	Working Capital Dem	-	-	-	25.00*	[ICRA]A2+; withdrawn
NA	Cash Credit	-	-	-	25.00^	[ICRA]BBB+ (Stable); withdrawn
NA	Cash Credit	-	-	-	35.00***	[ICRA]BBB+ (Stable); withdrawn
NA	Bank Guarantee	-	-	-	30.00**	[ICRA]A2+; withdrawn

\*Sublimit of 25.00 crore of pre-shipment export credit facility

\*\*Sublimit of Rs. 30.00 crore of letter of credit facility

\*\*\*Sublimit of Rs. 35.00 crore of packing credit

^Sublimit of Rs. 25.00 crore of pre-shipment export credit facility

^^Sublimit of Rs. 25.00 crore of letter of credit facility

Source: Alivira Animal Health Limited



### **ANALYST CONTACTS**

Subrata Ray +91 22 6114 3408 subrata@icraindia.com

Abhilash Mishra +91 22 6114 3421 abhilash.mishra@icraindia.com Kinjal Shah +91 22 6114 3442 kinjal.shah@icraindia.com

### **RELATIONSHIP CONTACT**

L. Shivakumar +91 22 6114 3406 shivakumar@icraindia.com

# MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani Tel: +91 124 4545 860 communications@icraindia.com

#### Helpline for business queries:

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

### **About ICRA Limited:**

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in



### **ICRA Limited**

#### **Corporate Office**

Building No. 8, 2nd Floor, Tower A; DLF Cyber City, Phase II; Gurgaon 122 002 Tel: +91 124 4545300 Email: <u>info@icraindia.com</u> Website: www.icra.in

#### **Registered Office**

1105, Kailash Building, 11th Floor; 26 Kasturba Gandhi Marg; New Delhi 110001 Tel: +91 11 23357940-50

#### Branches

Mumbai+ (91 22) 24331046/53/62/74/86/87Chennai+ (91 44) 2434 0043/9659/8080, 2433 0724/3293/3294,Kolkata+ (91 33) 2287 8839 /2287 6617/2283 1411/2280 0008,Bangalore+ (91 80) 2559 7401/4049Ahmedabad+(91 79) 2658 4924/5049/2008Hyderabad+ (91 40) 2373 5061/7251Pune+ (91 20) 2556 0194/6606 9999

© Copyright, 2019 ICRA Limited. All Rights Reserved.

#### Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents